{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:40:25Z","timestamp":1780479625984,"version":"3.54.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2628-B-006-032"],"award-info":[{"award-number":["109-2628-B-006-032"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["110-2320-B-006-051"],"award-info":[{"award-number":["110-2320-B-006-051"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00018-021-03950-3","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T13:03:44Z","timestamp":1635339824000},"page":"7681-7692","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by inhibition of HIF-1\u03b1-VEGF pathway"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4150-5481","authenticated-orcid":false,"given":"Yi-Hsun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsiang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Chen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Huei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"3950_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nm.4059","volume":"22","author":"JS Joyal","year":"2016","unstructured":"Joyal JS, Sun Y, Gantner ML, Shao Z, Evans LP, Saba N, Fredrick T, Burnim S, Kim JS, Patel G, Juan AM, Hurst CG, Hatton CJ, Cui Z, Pierce KA, Bherer P, Aguilar E, Powner MB, Vevis K, Boisvert M, Fu Z, Levy E, Fruttiger M, Packard A, Rezende FA, Maranda B, Sapieha P, Chen J, Friedlander M, Clish CB, Smith LE (2016) Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat Med 22:439\u2013445. https:\/\/doi.org\/10.1038\/nm.4059","journal-title":"Nat Med"},{"key":"3950_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-cellbio-092910-154002","volume":"27","author":"AS Chung","year":"2011","unstructured":"Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 27:563\u2013584. https:\/\/doi.org\/10.1146\/annurev-cellbio-092910-154002","journal-title":"Annu Rev Cell Dev Biol"},{"key":"3950_CR3","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, Group AS (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"3950_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"3950_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ, Group B-RC (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"3950_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"JA Wells","year":"2015","unstructured":"Diabetic Retinopathy Clinical Research N, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193\u20131203. https:\/\/doi.org\/10.1056\/NEJMoa1414264","journal-title":"N Engl J Med"},{"key":"3950_CR7","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/380439a0","volume":"380","author":"N Ferrara","year":"1996","unstructured":"Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O\u2019Shea KS, Powell-Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439\u2013442. https:\/\/doi.org\/10.1038\/380439a0","journal-title":"Nature"},{"key":"3950_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials Research G, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:1751\u20131761. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.045","journal-title":"Ophthalmology"},{"key":"3950_CR9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/IAE.0000000000000053","volume":"34","author":"I Lains","year":"2014","unstructured":"Lains I, Figueira J, Santos AR, Baltar A, Costa M, Nunes S, Farinha C, Pinto R, Henriques J, Silva R (2014) Choroidal thickness in diabetic retinopathy: the influence of antiangiogenic therapy. Retina 34:1199\u20131207. https:\/\/doi.org\/10.1097\/IAE.0000000000000053","journal-title":"Retina"},{"key":"3950_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.2337\/dc13-1990","volume":"37","author":"N Cheung","year":"2014","unstructured":"Cheung N, Wong IY, Wong TY (2014) Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. Diabetes Care 37:900\u2013905. https:\/\/doi.org\/10.2337\/dc13-1990","journal-title":"Diabetes Care"},{"key":"3950_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.semperi.2015.12.006","volume":"40","author":"KD Beharry","year":"2016","unstructured":"Beharry KD, Valencia GB, Lazzaro DR, Aranda JV (2016) Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity. Semin Perinatol 40:189\u2013202. https:\/\/doi.org\/10.1053\/j.semperi.2015.12.006","journal-title":"Semin Perinatol"},{"key":"3950_CR12","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, Purcaro V, Giannantonio C, Papacci P, Romagnoli C (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121:2212\u20132219. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015","journal-title":"Ophthalmology"},{"issue":"327\u2013333","key":"3950_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(327\u2013333):e1. https:\/\/doi.org\/10.1016\/j.ajo.2011.07.005","journal-title":"Am J Ophthalmol"},{"key":"3950_CR14","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM, Comparing Alternative Ranibizumab Dosages for S and Efficacy in Retinopathy of Prematurity Study G (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 172:278\u2013286. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr"},{"key":"3950_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","volume":"124","author":"JE Grunwald","year":"2017","unstructured":"Grunwald JE, Pistilli M, Daniel E, Ying GS, Pan W, Jaffe GJ, Toth CA, Hagstrom SA, Maguire MG, Martin DF, Comparison of Age-Related Macular Degeneration Treatments Trials Research G (2017) Incidence and growth of geographic atrophy during 5 years of comparison of age-related macular degeneration treatments trials. Ophthalmology 124:97\u2013104. https:\/\/doi.org\/10.1016\/j.ophtha.2016.09.012","journal-title":"Ophthalmology"},{"key":"3950_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002675","volume":"3","author":"EJ Kuiper","year":"2008","unstructured":"Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I, Van Noorden CJ, Goldschmeding R, Schlingemann RO (2008) The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS ONE 3:e2675. https:\/\/doi.org\/10.1371\/journal.pone.0002675","journal-title":"PLoS ONE"},{"key":"3950_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr, Saravia M, Avery RL, Wu L, Farah ME, Pieramici DJ, Berrocal MH, Sanchez JG (2008) Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92:213\u2013216. https:\/\/doi.org\/10.1136\/bjo.2007.127142","journal-title":"Br J Ophthalmol"},{"key":"3950_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s10792-018-0874-6","volume":"39","author":"F Yenihayat","year":"2019","unstructured":"Yenihayat F, Ozkan B, Kasap M, Karabas VL, Guzel N, Akpinar G, Pirhan D (2019) Vitreous IL-8 and VEGF levels in diabetic macular edema with or without subretinal fluid. Int Ophthalmol 39:821\u2013828. https:\/\/doi.org\/10.1007\/s10792-018-0874-6","journal-title":"Int Ophthalmol"},{"key":"3950_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ophtha.2008.09.037","volume":"116","author":"H Funatsu","year":"2009","unstructured":"Funatsu H, Noma H, Mimura T, Eguchi S, Hori S (2009) Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116:73\u201379. https:\/\/doi.org\/10.1016\/j.ophtha.2008.09.037","journal-title":"Ophthalmology"},{"key":"3950_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","volume":"136","author":"RK Maturi","year":"2018","unstructured":"Maturi RK, Glassman AR, Liu D, Beck RW, Bhavsar AR, Bressler NM, Jampol LM, Melia M, Punjabi OS, Salehi-Had H, Sun JK, Diabetic Retinopathy Clinical Research N (2018) Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol 136:29\u201338. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4914","journal-title":"JAMA Ophthalmol"},{"key":"3950_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12886-018-1022-9","volume":"19","author":"V Castro-Navarro","year":"2019","unstructured":"Castro-Navarro V, Cervera-Taulet E, Navarro-Palop C, Monferrer-Adsuara C, Hernandez-Bel L, Montero-Hernandez J (2019) Intravitreal dexamethasone implant Ozurdex(R) in naive and refractory patients with different subtypes of diabetic macular edema. BMC Ophthalmol 19:15. https:\/\/doi.org\/10.1186\/s12886-018-1022-9","journal-title":"BMC Ophthalmol"},{"key":"3950_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1080\/09273948.2016.1184284","volume":"25","author":"JMF Adeniran","year":"2017","unstructured":"Adeniran JMF, Jusufbegovic D, Schaal S (2017) Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm 25:834\u2013840. https:\/\/doi.org\/10.1080\/09273948.2016.1184284","journal-title":"Ocul Immunol Inflamm"},{"key":"3950_CR23","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1073\/pnas.78.4.2249","volume":"78","author":"CT Esmon","year":"1981","unstructured":"Esmon CT, Owen WG (1981) Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78:2249\u20132252","journal-title":"Proc Natl Acad Sci USA"},{"key":"3950_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1423-0127-19-34","volume":"19","author":"YH Li","year":"2012","unstructured":"Li YH, Kuo CH, Shi GY, Wu HL (2012) The role of thrombomodulin lectin-like domain in inflammation. J Biomed Sci 19:34. https:\/\/doi.org\/10.1186\/1423-0127-19-34","journal-title":"J Biomed Sci"},{"key":"3950_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nm0505-475","volume":"11","author":"C Esmon","year":"2005","unstructured":"Esmon C (2005) Do-all receptor takes on coagulation, inflammation. Nat Med 11:475\u2013477. https:\/\/doi.org\/10.1038\/nm0505-475","journal-title":"Nat Med"},{"key":"3950_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00281-011-0282-8","volume":"34","author":"EM Conway","year":"2012","unstructured":"Conway EM (2012) Thrombomodulin and its role in inflammation. Semin Immunopathol 34:107\u2013125. https:\/\/doi.org\/10.1007\/s00281-011-0282-8","journal-title":"Semin Immunopathol"},{"key":"3950_CR27","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1182\/blood-2008-03-142760","volume":"112","author":"CS Shi","year":"2008","unstructured":"Shi CS, Shi GY, Hsiao HM, Kao YC, Kuo KL, Ma CY, Kuo CH, Chang BI, Chang CF, Lin CH, Wong CH, Wu HL (2008) Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 112:3661\u20133670. https:\/\/doi.org\/10.1182\/blood-2008-03-142760","journal-title":"Blood"},{"key":"3950_CR28","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1182\/blood-2011-08-376038","volume":"119","author":"CH Kuo","year":"2012","unstructured":"Kuo CH, Chen PK, Chang BI, Sung MC, Shi CS, Lee JS, Chang CF, Shi GY, Wu HL (2012) The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. Blood 119:1302\u20131313. https:\/\/doi.org\/10.1182\/blood-2011-08-376038","journal-title":"Blood"},{"key":"3950_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/bjo.81.3.228","volume":"81","author":"M Boulton","year":"1997","unstructured":"Boulton M, Gregor Z, McLeod D, Charteris D, Jarvis-Evans J, Moriarty P, Khaliq A, Foreman D, Allamby D, Bardsley B (1997) Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol 81:228\u2013233. https:\/\/doi.org\/10.1136\/bjo.81.3.228","journal-title":"Br J Ophthalmol"},{"key":"3950_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.20020077","volume":"196","author":"EM Conway","year":"2002","unstructured":"Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G (2002) The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 196:565\u2013577. https:\/\/doi.org\/10.1084\/jem.20020077","journal-title":"J Exp Med"},{"key":"3950_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2019.11.012","volume":"22","author":"CC Lim","year":"2020","unstructured":"Lim CC, Peng IC, Huang YH (2020) Safety of intrastromal injection of polyhexamethylene biguanide and propamidine isethionate in a rabbit model. J Adv Res 22:1\u20136. https:\/\/doi.org\/10.1016\/j.jare.2019.11.012","journal-title":"J Adv Res"},{"key":"3950_CR32","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith LE, Wesolowski E, McLellan A, Kostyk SK, D\u2019Amato R, Sullivan R, D\u2019Amore PA (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35:101\u2013111","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3950_CR33","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/nprot.2009.187","volume":"4","author":"KM Connor","year":"2009","unstructured":"Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, Sapieha P, Stahl A, Willett KL, Smith LE (2009) Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 4:1565\u20131573. https:\/\/doi.org\/10.1038\/nprot.2009.187","journal-title":"Nat Protoc"},{"key":"3950_CR34","doi-asserted-by":"publisher","first-page":"16767","DOI":"10.1074\/jbc.M901790200","volume":"284","author":"DR Mole","year":"2009","unstructured":"Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ (2009) Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 284:16767\u201316775. https:\/\/doi.org\/10.1074\/jbc.M901790200","journal-title":"J Biol Chem"},{"key":"3950_CR35","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","volume":"30","author":"WG Kaelin Jr","year":"2008","unstructured":"Kaelin WG Jr, Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30:393\u2013402. https:\/\/doi.org\/10.1016\/j.molcel.2008.04.009","journal-title":"Mol Cell"},{"key":"3950_CR36","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","volume":"270","author":"GL Wang","year":"1995","unstructured":"Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270:1230\u20131237. https:\/\/doi.org\/10.1074\/jbc.270.3.1230","journal-title":"J Biol Chem"},{"key":"3950_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neuint.2019.03.008","volume":"128","author":"Y Miwa","year":"2019","unstructured":"Miwa Y, Hoshino Y, Shoda C, Jiang X, Tsubota K, Kurihara T (2019) Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model. Neurochem Int 128:21\u201331. https:\/\/doi.org\/10.1016\/j.neuint.2019.03.008","journal-title":"Neurochem Int"},{"key":"3950_CR38","first-page":"182","volume":"40","author":"H Ozaki","year":"1999","unstructured":"Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, Yamada H, Hackett SF, Okamoto N, Zack DJ, Semenza GL, Campochiaro PA (1999) Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40:182\u2013189","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3950_CR39","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1167\/iovs.13-13397","volume":"55","author":"CC Tokunaga","year":"2014","unstructured":"Tokunaga CC, Mitton KP, Dailey W, Massoll C, Roumayah K, Guzman E, Tarabishy N, Cheng M, Drenser KA (2014) Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 55:1884\u20131892. https:\/\/doi.org\/10.1167\/iovs.13-13397","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3950_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ijcard.2014.01.009","volume":"172","author":"TH Chao","year":"2014","unstructured":"Chao TH, Tsai WC, Chen JY, Liu PY, Chung HC, Tseng SY, Kuo CH, Shi GY, Wu HL, Li YH (2014) Soluble thrombomodulin is a paracrine anti-apoptotic factor for vascular endothelial protection. Int J Cardiol 172:340\u2013349. https:\/\/doi.org\/10.1016\/j.ijcard.2014.01.009","journal-title":"Int J Cardiol"},{"key":"3950_CR41","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(05)77134-8","volume":"354","author":"V Salomaa","year":"1999","unstructured":"Salomaa V, Wu KK (1999) Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet 354:1646\u20131647. https:\/\/doi.org\/10.1016\/S0140-6736(05)77134-8","journal-title":"Lancet"},{"key":"3950_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"key":"3950_CR43","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jcmm.12235","volume":"18","author":"SW Park","year":"2014","unstructured":"Park SW, Kim JH, Kim KE, Jeong MH, Park H, Park B, Suh YG, Park WJ, Kim JH (2014) Beta-lapachone inhibits pathological retinal neovascularization in oxygen-induced retinopathy via regulation of HIF-1alpha. J Cell Mol Med 18:875\u2013884. https:\/\/doi.org\/10.1111\/jcmm.12235","journal-title":"J Cell Mol Med"},{"key":"3950_CR44","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/emboj\/cdg117","volume":"22","author":"M Morita","year":"2003","unstructured":"Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O, Kawauchi S, Ema M, Shibahara S, Udono T, Tomita K, Tamai M, Sogawa K, Yamamoto M, Fujii-Kuriyama Y (2003) HLF\/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO J 22:1134\u20131146. https:\/\/doi.org\/10.1093\/emboj\/cdg117","journal-title":"EMBO J"},{"key":"3950_CR45","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI13776","volume":"109","author":"V Poulaki","year":"2002","unstructured":"Poulaki V, Qin W, Joussen AM, Hurlbut P, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP (2002) Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. J Clin Invest 109:805\u2013815. https:\/\/doi.org\/10.1172\/JCI13776","journal-title":"J Clin Invest"},{"key":"3950_CR46","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1172\/JCI65157","volume":"122","author":"T Kurihara","year":"2012","unstructured":"Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M (2012) Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest 122:4213\u20134217. https:\/\/doi.org\/10.1172\/JCI65157","journal-title":"J Clin Invest"},{"key":"3950_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/JPER.20-0732","author":"LY Chang","year":"2021","unstructured":"Chang LY, Lai CH, Kuo CH, Chang BI, Wu HL, Cheng TL (2021) Recombinant thrombomodulin lectin-like domain attenuates porphyromonas gingivalis lipopolysaccharide-induced osteoclastogenesis and periodontal bone resorption. J Periodontol. https:\/\/doi.org\/10.1002\/JPER.20-0732","journal-title":"J Periodontol"},{"key":"3950_CR48","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/ajt.16269","volume":"21","author":"J Kawasoe","year":"2021","unstructured":"Kawasoe J, Uchida Y, Miyauchi T, Kadono K, Hirao H, Saga K, Watanabe T, Ueda S, Terajima H, Uemoto S (2021) The lectin-like domain of thrombomodulin is a drug candidate for both prophylaxis and treatment of liver ischemia and reperfusion injury in mice. Am J Transplant 21:540\u2013551. https:\/\/doi.org\/10.1111\/ajt.16269","journal-title":"Am J Transplant"},{"key":"3950_CR49","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/cas.12937","volume":"107","author":"F Zhang","year":"2016","unstructured":"Zhang F, Duan S, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y (2016) Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cancer Sci 107:746\u2013754. https:\/\/doi.org\/10.1111\/cas.12937","journal-title":"Cancer Sci"},{"key":"3950_CR50","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.1038\/sj.onc.1208719","volume":"24","author":"Q Xu","year":"2005","unstructured":"Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552\u20135560. https:\/\/doi.org\/10.1038\/sj.onc.1208719","journal-title":"Oncogene"},{"key":"3950_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/jpi.12473","volume":"64","author":"Y Xu","year":"2018","unstructured":"Xu Y, Lu X, Hu Y, Yang B, Tsui CK, Yu S, Lu L, Liang X (2018) Melatonin attenuated retinal neovascularization and neuroglial dysfunction by inhibition of HIF-1alpha-VEGF pathway in oxygen-induced retinopathy mice. J Pineal Res 64:e12473. https:\/\/doi.org\/10.1111\/jpi.12473","journal-title":"J Pineal Res"},{"key":"3950_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/iub.1358","volume":"67","author":"A Szade","year":"2015","unstructured":"Szade A, Grochot-Przeczek A, Florczyk U, Jozkowicz A, Dulak J (2015) Cellular and molecular mechanisms of inflammation-induced angiogenesis. IUBMB Life 67:145\u2013159. https:\/\/doi.org\/10.1002\/iub.1358","journal-title":"IUBMB Life"},{"key":"3950_CR53","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ijcard.2005.09.015","volume":"111","author":"SH Chan","year":"2006","unstructured":"Chan SH, Chen JH, Li YH, Lin LJ, Tsai LM (2006) Increasing post-event plasma thrombomodulin level associates with worse outcome in survival of acute coronary syndrome. Int J Cardiol 111:280\u2013285. https:\/\/doi.org\/10.1016\/j.ijcard.2005.09.015","journal-title":"Int J Cardiol"},{"key":"3950_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/clc.4960240506","volume":"24","author":"M Ileri","year":"2001","unstructured":"Ileri M, Hisar I, Yetkin E, Kosar F, Cehreli S, Korkmaz S, Demirkan D (2001) Increased levels of plasma thrombomodulin in patients with acute myocardial infarction who had thrombolytic therapy and achieved successful reperfusion. Clin Cardiol 24:377\u2013379. https:\/\/doi.org\/10.1002\/clc.4960240506","journal-title":"Clin Cardiol"},{"key":"3950_CR55","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/bf00311430","volume":"25","author":"T Iba","year":"1995","unstructured":"Iba T, Yagi Y, Kidokoro A, Fukunaga M, Fukunaga T (1995) Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surg Today 25:585\u2013590. https:\/\/doi.org\/10.1007\/bf00311430","journal-title":"Surg Today"},{"key":"3950_CR56","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00125-006-0568-x","volume":"50","author":"B Thorand","year":"2007","unstructured":"Thorand B, Baumert J, Herder C, Meisinger C, Koenig W (2007) Soluble thrombomodulin as a predictor of type 2 diabetes: results from the MONICA\/KORA Augsburg case-cohort study, 1984\u20131998. Diabetologia 50:545\u2013548. https:\/\/doi.org\/10.1007\/s00125-006-0568-x","journal-title":"Diabetologia"},{"key":"3950_CR57","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/SLA.0b013e31827df7cb","volume":"258","author":"CH Lai","year":"2013","unstructured":"Lai CH, Shi GY, Lee FT, Kuo CH, Cheng TL, Chang BI, Ma CY, Hsu FC, Yang YJ, Wu HL (2013) Recombinant human thrombomodulin suppresses experimental abdominal aortic aneurysms induced by calcium chloride in mice. Ann Surg 258:1103\u20131110. https:\/\/doi.org\/10.1097\/SLA.0b013e31827df7cb","journal-title":"Ann Surg"},{"key":"3950_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122491","volume":"10","author":"YH Huang","year":"2015","unstructured":"Huang YH, Ching-Chang I, Kuo CH, Hsu YY, Lee FT, Shi GY, Tseng SH, Wu HL (2015) Thrombomodulin promotes corneal epithelial wound healing. PLoS ONE 10:e0122491. https:\/\/doi.org\/10.1371\/journal.pone.0122491","journal-title":"PLoS ONE"},{"key":"3950_CR59","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1172\/JCI22782","volume":"115","author":"K Abeyama","year":"2005","unstructured":"Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I (2005) The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 115:1267\u20131274. https:\/\/doi.org\/10.1172\/JCI22782","journal-title":"J Clin Invest"},{"key":"3950_CR60","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/j.1538-7836.2006.02033.x","volume":"4","author":"M Van de Wouwer","year":"2006","unstructured":"Van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J, Daha MR, Conway EM (2006) The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 4:1813\u20131824. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.02033.x","journal-title":"J Thromb Haemost"},{"key":"3950_CR61","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1167\/iovs.18-25878","volume":"60","author":"M Krogh Nielsen","year":"2019","unstructured":"Krogh Nielsen M, Subhi Y, Molbech CR, Falk MK, Nissen MH, Sorensen TL (2019) Systemic levels of interleukin-6 correlate with progression rate of geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 60:202\u2013208. https:\/\/doi.org\/10.1167\/iovs.18-25878","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3950_CR62","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/IAE.0000000000001210","volume":"37","author":"RJ Hillier","year":"2017","unstructured":"Hillier RJ, Ojaimi E, Wong DT, Mak MY, Berger AR, Kohly RP, Kertes PJ, Forooghian F, Boyd SR, Eng K, Altomare F, Giavedoni LR, Nisenbaum R, Muni RH (2017) Aqueous humor cytokine levels as biomarkers of disease severity in diabetic macular edema. Retina 37:761\u2013769. https:\/\/doi.org\/10.1097\/IAE.0000000000001210","journal-title":"Retina"},{"key":"3950_CR63","first-page":"574","volume":"18","author":"H Miao","year":"2012","unstructured":"Miao H, Tao Y, Li XX (2012) Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization. Mol Vis 18:574\u2013580","journal-title":"Mol Vis"},{"key":"3950_CR64","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1111\/j.1755-3768.2012.02414.x","volume":"90","author":"JB Jonas","year":"2012","unstructured":"Jonas JB, Tao Y, Neumaier M, Findeisen P (2012) Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration. Acta Ophthalmol 90:e381\u2013e388. https:\/\/doi.org\/10.1111\/j.1755-3768.2012.02414.x","journal-title":"Acta Ophthalmol"},{"key":"3950_CR65","doi-asserted-by":"publisher","first-page":"366","DOI":"10.18240\/ijo.2017.03.07","volume":"10","author":"SJ Chu","year":"2017","unstructured":"Chu SJ, Zhang ZH, Wang M, Xu HF (2017) Effect of bevacizumab on the expression of fibrosis-related inflammatory mediators in ARPE-19 cells. Int J Ophthalmol 10:366\u2013371. https:\/\/doi.org\/10.18240\/ijo.2017.03.07","journal-title":"Int J Ophthalmol"},{"key":"3950_CR66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1097\/IAE.0000000000001685","volume":"38","author":"Y Yonekawa","year":"2018","unstructured":"Yonekawa Y, Wu WC, Nitulescu CE, Chan RVP, Thanos A, Thomas BJ, Todorich B, Drenser KA, Trese MT, Capone A Jr (2018) Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab. Retina 38:1079\u20131083. https:\/\/doi.org\/10.1097\/IAE.0000000000001685","journal-title":"Retina"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-03950-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03950-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T07:15:21Z","timestamp":1638170121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-03950-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":66,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3950"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-03950-3","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"24 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All efforts were made to reduce both animal suffering and the number of animals used. All animal studies and procedures adhered to the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee at National Cheng Kung University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}